April 20, 2023:
The commission agrees to use the combined Measles-Rubella-Mumps-Varicella (MRMV) vaccine as a second dose, but consensus is not reached regarding the age of application. It is suggested to evaluate programmatic aspects related to the modification of age. It recommends continuing and strengthening commitments to sustain measles elimination, considering social and economic aspects and reinforcing field vaccination. The commission recommends the incorporation of a sextuple vaccine into the National Vaccination Calendar (CNV) to optimize it. At the time of discussion, the only available vaccine contains acellular pertussis component; the majority agrees that this vaccine could be used to simplify the schedule. It is mentioned that a sextuple vaccine combined with whole-cell pertussis component might also be available, so it is agreed to evaluate the evidence when it becomes available for consideration.